A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer

被引：7

作者：

Puglisi, Fabio ^{[1
]}

Bisagni, Giancarlo ^{[2
]}

Ciccarese, Mariangela ^{[3
]}

Fontanella, Caterina ^{[1
]}

Gamucci, Teresa ^{[4
]}

Leo, Luigi ^{[5
]}

Molino, Annamaria ^{[6
]}

Silva, Rosa Rita ^{[7
]}

Marchetti, Paolo ^{[8
,9
]}

机构：

[1] Univ Udine, Dept Med & Biol Sci, Udine, Italy

[2] Azienda Osped ASMN, Dept Oncol, Oncol Unit, Ist Ricovero & Cura Carattere Sci, Reggio Emilia, Italy

[3] Vito Fazzi Hosp, Dept Med Oncol, Lecce, Italy

[4] ASL Frosinone, Med Oncol Unit, Frosinone, Italy

[5] Azienda Osped Colli, Oncol Unit, Naples, Italy

[6] Univ Verona, Verona, Italy

[7] ASUR Marche AV2 Fabriano, Med Oncol Unit, Fabriano, Italy

[8] Sapienza Univ Rome, Med Oncol, St Andrea Hosp, Rome, Italy

[9] IDI IRCCS, Rome, Italy

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 22期

关键词：

angiogenesis; bevacizumab; breast cancer; PROGRESSION-FREE SURVIVAL; PHASE-III TRIAL; CONTAINING THERAPY; OPEN-LABEL; NEOADJUVANT CHEMOTHERAPY; PLUS BEVACIZUMAB; TARGETED THERAPIES; AND/OR BEVACIZUMAB; LOCALLY RECURRENT; CLINICAL-PRACTICE;

D O I：

10.2217/fon-2016-0295

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To gain consensus on the role of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer, a panel of expert oncologists experienced in treating patients with metastatic breast cancer in Italy participated in a Delphi consensus study. The panel reached a full consensus on the efficacy of bevacizumab plus paclitaxel and the clinical meaningfulness of the progression-free survival benefit compared with paclitaxel alone, despite the lack of an overall survival effect in clinical trials. The participants agreed that real-world data support the effectiveness and well-defined safety profile of the regimen. Views on the use of bevacizumab plus paclitaxel in specific patient populations were not unanimous and clinical judgment remains important. Nevertheless, a high level of agreement was reached.

引用

页码：2589 / 2602

页数：14

共 50 条

[21] Bevacizumab in the treatment of HER2-negative breast cancer
Lorusso, Vito
BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04): : 813 - 821
[22] First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study
Schneeweiss, Andreas
Forster, Frank
Tesch, Hans
Aktas, Bahriye
Gluz, Oleg
Geberth, Matthias
Hertz-Eichenrode, Martin M.
Schonegg, Winfried
Schumacher, Claudia
Kutscheidt, Andreas
Kiewitz, Claudia
Klawitter, Sandra
Schmidt, Marcus
ANTICANCER RESEARCH, 2016, 36 (03) : 967 - 974
[23] Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
Miles, D. W.
de Haas, S. L.
Dirix, L. Y.
Romieu, G.
Chan, A.
Pivot, X.
Tomczak, P.
Provencher, L.
Cortes, J.
Delmar, P. R.
Scherer, S. J.
BRITISH JOURNAL OF CANCER, 2013, 108 (05) : 1052 - 1060
[24] A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01)
Hurvitz, Sara A.
Allen, Heather J.
Moroose, Rebecca L.
Chan, David
Hagenstad, Christopher
Applebaum, Steven H.
Patel, Giribala
Hu, Eddie H.
Ryba, Nancy
Lin, Lii-Shin
Wang, HeJing
Glaspy, John
Slamon, Dennis J.
Kabbinavar, Fairooz
CLINICAL BREAST CANCER, 2010, 10 (04) : 307 - 312
[25] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Salvador, J.
Manso, L.
de la Haba, J.
Jaen, A.
Ciruelos, E.
de Villena, M. C.
Gil, M.
Murias, A.
Galan, A.
Jara, C.
Bayo, J.
Baena, J. M.
Casal, J.
Mel, J. R.
Blancas, I.
Sanchez Rvira, P.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (02): : 160 - 166
[26] Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
D W Miles
S L de Haas
L Y Dirix
G Romieu
A Chan
X Pivot
P Tomczak
L Provencher
J Cortés
P R Delmar
S J Scherer
British Journal of Cancer, 2013, 108 : 1052 - 1060
[27] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
J. Salvador
L. Manso
J. de la Haba
A. Jaen
E. Ciruelos
M. C. de Villena
M. Gil
A. Murias
A. Galan
C. Jara
J. Bayo
J. M. Baena
J. Casal
J. R. Mel
I. Blancas
P. Sanchez Rvira
Clinical and Translational Oncology, 2015, 17 : 160 - 166
[28] Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials
Liu, Xiaoqun
Liu, Xiangdong
Qiao, Tiankui
Chen, Wei
Yuan, Sujuan
ONCOTARGETS AND THERAPY, 2016, 9 : 3771 - 3781
[29] Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies
Yamamoto, Yutaka
Yamashiro, Hiroyasu
Schneeweiss, Andreas
Muller, Volkmar
Gluz, Oleg
Klare, Peter
Aktas, Bahriye
Magdolna, Dank
Budi, Laszlo
Piko, Bela
Mangel, Laszlo
Toi, Masakazu
Morita, Satoshi
Ohno, Shinji
BREAST CANCER, 2023, 30 (01) : 88 - 100
[30] Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Fabi, Alessandra
Russillo, Michelangelo
Ferretti, Gianluigi
Metro, Giulio
Nistico, Cecilia
Papaldo, Paola
De Vita, Ferdinando
D'Auria, Giuliana
Vidiri, Antonello
Giannarelli, Diana
Cognetti, Francesco
BMC CANCER, 2012, 12

← 1 2 3 4 5 →